SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Novus Capital Corp (CIK 0001807707) — Aug 11, 2022

Novus Capital Corp (CIK 0001807707)
Date: Aug. 11, 2022 · CIK: 0001807707 · Accession: 0000000000-22-008560

AI Filing Summary & Sentiment

File numbers found in text: 333-266502

Date
August 11, 2022
Author
Not clearly detected
Form
UPLOAD
Company
Novus Capital Corp (CIK 0001807707)

Letter

United States securities and exchange commission logo August 11, 2022 Loren Eggleton Chief Financial Officer AppHarvest, Inc. 500 Appalachian Way Morehead, KY 40351 Re:AppHarvest, Inc. Registration Statement on Form S-3 Filed August 3, 2022 File No. 333-266502 Dear Mr. Eggleton: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John McKenna, Esq.

Show Raw Text
United States securities and exchange commission logo
August 11, 2022
Loren Eggleton
Chief Financial Officer
AppHarvest, Inc.
500 Appalachian Way
Morehead, KY 40351
Re:AppHarvest, Inc.
Registration Statement on Form S-3
Filed August 3, 2022
File No. 333-266502
Dear Mr. Eggleton:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       John McKenna, Esq.